About the Rare Tumors Program
The Rare Tumors Program at Texas Children’s Cancer Center is the only pediatric rare tumors program in the southwest United States. Located at Texas Children’s Hospital, we are dedicated to providing exceptional care and new treatment options to children and adolescents with rare malignancies.
As part of the largest pediatric cancer center in the United States, The Rare Tumors Program cares for a substantial number of children who have been diagnosed with rare tumors. Our multidisciplinary team of pediatric oncologists, pathologists, surgeons, radiologists, geneticists and researchers work together to achieve the best outcome for every patient.
Rare tumors in children range from cancers that occur only during childhood (e.g., pleuropulmonary blastoma) to cancers that primarily occur in adults but that can rarely occur in children (e.g., melanoma and colorectal cancer).
Often, no standard diagnostic or treatment protocols exist for rare tumors. We have developed standardized treatment regimens for multiple childhood rare tumors and when applicable, we use advanced molecular diagnostic techniques to facilitate a timely and accurate diagnoses.
The rare tumors we treat include:
- Nasopharyngeal carcinoma
- Melanoma and dysplastic nevus
- Adrenocortical neoplasm
- Gastrointestinal stromal tumors (GIST)
- Carcinoid tumors
- Thyroid malignancies
- NUT midline carcinoma
- Pleuropulmonary blastoma
- Rhabdoid tumors
- Germ cell tumors
- Inflammatory myofibroblastic tumor
- Giant cell granuloma/tumor
- Colorectal carcinomas
- Desmoplastic small round cell tumor
- Renal cell carcinoma
- Liver Tumors
- Non-rhabdomyosarcoma soft tissue sarcomas, including:
- Fibroblastic/myofibroblastic tumors – solitary fibrous tumor, hemangiopericytoma, low-grade myofibroblastic sarcoma, myxoinflammatory fibroblastic sarcoma, adult fibrosarcoma, myxofibrosarcoma, low-grade fibromyxoid sarcoma (or hyalinizing spindle cell tumor), sclerosing epithelioid fibrosarcoma
- Fibrohistiocytic tumors – plexiform fibrohistiocytic tumor, giant cell tumor of soft tissues, pleomorphic ‘MFH’/undifferentiated pleomorphic sarcoma, giant cell ‘MFH’/undifferentiated pleomorphic sarcoma with giant cells, inflammatory ‘MFH’/undifferentiated pleomorphic sarcoma with prominent inflammation
- Smooth muscle tumors – leiomyosarcoma
- Pericytic (perivascular) tumors – malignant glomus tumour, glomangiosarcoma
- Vascular tumors – angiosarcoma of soft tissue
- Chondro-osseous tumors – mesenchymal chondrosarcoma, extraskeletal osteosarcoma
- Tumors of uncertain differentiation – angiomatoid fibrous histiocytoma, ossifying fibromyxoid tumor, myoepithelioma, parachordoma, synovial sarcoma, epithelioid sarcoma, alveolar soft part sarcoma, clear cell sarcoma of soft tissue, extraskeletal myxoid chondrosarcoma (“chordoid type”), malignant mesenchymoma, neoplasms with perivascular epithelioid cell differentiation (PEComa), clear cell myomelanocytic tumor, intimal sarcoma
- Malignant peripheral nerve sheath tumor
- Dermatofibrosarcoma protuberans
- Embryonal sarcoma of the liver
- Soft tissue sarcomas, not otherwise specified
Our research is focused on understanding the genetic basis of rare tumors and identifying novel treatment targets. We collaborate with other pediatric treatment centers—both nationally and internationally to improve the diagnosis and treatment of rare tumors. We also actively participate in national registries for individual tumors and are developing registries for tumors, which do not have a dedicated registry.
We welcome oncologists to contact us for second opinion consultations about the care and management of individual patients.
Donations to support the Rare Tumors Program may be made online. Please make sure to specify under ‘Comments’ that the donation is for the Rare Tumors Program.